menu
    • menu

    Company profile for reMYND

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    reMYND NV is a dynamic biotech company located in Leuven (Belgium) that actively drives R&D in the field of protein misfolding diseases, among others Alzheimer’s disease (AD) and Parkinson’s disease (PD).The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD (counteracting TAU and aSyn toxicity, respectively). The C...
    reMYND NV is a dynamic biotech company located in Leuven (Belgium) that actively drives R&D in the field of protein misfolding diseases, among others Alzheimer’s disease (AD) and Parkinson’s disease (PD).The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD (counteracting TAU and aSyn toxicity, respectively). The Contract Research Unit offers extensive experience in the testing of experimental Alzheimer therapies in its unique and proprietary transgenic mouse models.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    reMYNDBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Gaston Geenslaan 1 BE-3001 Leuven (Heverlee)
    Telephone
    Telephone
    +32 16 75 14 20
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.remynd.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    reMYND’s Alzheimer program reports excellent brain exposure and safety profile
    reMYND’s Alzheimer program reports excellent brain exposure and safety profile

    03 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/03/2434152/0/en/reMYND-s-novel-Alzheimer-program-reports-excellent-brain-exposure-and-safety-profile-in-Phase-1-transitioning-into-Phase-2a.html

    GLOBENEWSWIRE
    03 May 2022
    Share Share
    reMYND and the US NINDS ETSP begin collaboration on epilepsy program
    reMYND and the US NINDS ETSP begin collaboration on epilepsy program

    04 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/04/2327275/0/en/reMYND-and-the-US-NINDS-Epilepsy-Therapy-Screening-Program-ETSP-begin-collaboration-on-epilepsy-program.html

    GLOBENEWSWIRE
    04 Nov 2021
    Share Share
    reMYND’s ReS19-T managing calcium homeostasis for Alzheimer’s, has moved
    reMYND’s ReS19-T managing calcium homeostasis for Alzheimer’s, has moved

    21 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/21/2318160/0/en/reMYND-s-ReS19-T-program-managing-calcium-homeostasis-for-Alzheimer-s-has-moved-to-MAD-phase-after-demonstrating-strong-safety-in-SAD-phase.html

    GLOBENEWSWIRE
    21 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search